We found that depletion of USP52 sensitives cells to PARP inhibitor in CtIP deubiquitination dependent manner in vitro and in vivo, suggesting that USP52 might be a new therapeutic target for bone cancers which are resistant to standard PARP inhibitor therapy. This evidence concerns the gene PAN2 and bone cancer.